Study identifier:D1950C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-label Positron Emission Tomography (PET) Study using 2 [18F] F A85380 to determine α4β2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-fertile Female (non-nicotine users) Healthy Volunteers
Healthy
Phase 1
Yes
AZD1446
All
11
Interventional
20 Years - 45 Years
Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor’s (NNRs) and to determine the relation between plasma concentration of AZD1446 and the occupancy at α4β2 NNRs.
Location
Location
Stockholm, Sweden
Arms | Assigned Interventions |
---|---|
Experimental: 2-[18F]-F-A85380 Single microdose | Radiation: 2-[18F]-F-A85380 iv, single dose |
Experimental: AZD1446 Single oral administration | Drug: AZD1446 Solution, oral, single dose |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.